CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2009--
Biogen Idec (NASDAQ: BIIB) today announced that Phillip A. Sharp, Ph.D.,
is retiring from the Company’s Board of Directors. Dr. Sharp, a Nobel
Laureate, co-founded the company in 1978 and has served as a director
since 1982.
“Dr. Sharp has been a pioneering force in this Company and this industry
for more than three decades, contributing enormously to both our
scientific and business achievements,” said Bruce R. Ross, Chairman of
the Board of Biogen Idec. “His work in the laboratory has led to major
medical advances, and his business judgment in the boardroom has helped
foster the growth of one of the world’s most successful biotechnology
companies. We are grateful for all he has contributed to Biogen Idec,
and wish him the best in his future endeavors.”
Dr. Sharp, 65, is Institute Professor at the Massachusetts Institute of
Technology and a faculty member in the Department of Biology and the
Center for Cancer Research. He served as Director in the Center for
Cancer Research from 1985 to 1991, as Head of the Department of Biology
from 1991 to 1999, and more recently as Director of the McGovern
Institute for Brain Research from 2000 to 2004 at the Massachusetts
Institute of Technology. Dr. Sharp was awarded a Nobel Prize in Medicine
in 1993 and was a National Medal of Science recipient in 2006.
About Biogen Idec
Biogen Idec creates new standards of care in therapeutic areas with high
unmet medical needs. Biogen Idec is a global leader in the discovery,
development, manufacturing, and commercialization of innovative
therapies. Patients in more than 90 countries benefit from Biogen Idec's
significant products that address diseases such as lymphoma, multiple
sclerosis, and rheumatoid arthritis. For product labeling, press
releases and additional information about the company, please visit
www.biogenidec.com.
Source: Biogen Idec
Biogen Idec Media:
Jennifer Neiman, 617-914-6524
Senior
Manager, Public Affairs
or
Biogen Idec Investor Relations:
Eric
Hoffman, 617-679-2812
Director, Investor Relations
